2,3-dihydro-2,3-dihydroxybenzoic acid | 18029-04-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羟基酸及其衍生物
• 英文名称: 2,3-dihydro-2,3-dihydroxybenzoic acid
• 英文别名: 5,6-Dihydroxycyclohexa-1,3-diene-1-carboxylic acid
• CAS: 18029-04-4
• 化学式: C₇H₈O₄
• 分子量: 156.138
• InChiKey: INCSWYKICIYAHB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  77.8
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  Chorisminsaeure 在 L-lactate dehydrogenase 、 AngB protein 、 EntC enzyme 、 还原型辅酶Ⅰ 、 magnesium chloride 作用下， 反应 0.67h， 生成 2,3-dihydro-2,3-dihydroxybenzoic acid
  参考文献：
  名称：

  Genetic and biochemical analyses of chromosome and plasmid gene homologues encoding ICL and ArCP domains in Vibrio anguillarum strain 775

  摘要：

  Anguibactin, the siderophore produced by Vibrio anguillarum 775 is synthesized from 2,3-dihydroxybenzoic acid (DHBA), cysteine and hydroxyhistamine via a nonribosomal peptide synthetase (NRPS) mechanism. Most of the genes encoding anguibactin biosynthetic proteins are harbored by the pJM1 plasmid. In this work we report the identification of a homologue of the plasmid-encoded angB on the chromosome of strain 775. The product of both genes harbor an isochorismate lyase (ICL) domain that converts isochorismic acid to 2,3-dihydro-2,3-dihydroxybenzoic acid, one of the steps of DHBA synthesis. We show in this work that both ICL domains are functional in the production of DHBA in V. anguillarum as well as in E. coli. Substitution by alanine of the aspartic acid residue in the active site of both ICL domains completely abolishes their isochorismate lyase activity in vivo. The two proteins also carry an aryl carrier protein (ArCP) domain. In contrast with the ICL domains only the plasmid encoded ArCP can participate in anguibactin production as determined by complementation analyses and site-directed mutagenesis in the active site of the plasmid encoded protein, S248A. The site-directed mutants, D37A in the ICL domain and S248A in the ArCP domain of the plasmid encoded AngB were also tested in vitro and clearly show the importance of each residue for the domain function and that each domain operates independently.

  DOI：

  10.1007/s10534-011-9416-7

文献信息

• PROCESS AND COMPOUNDS FOR THE MANUFACTURE OF OSELTAMIVIR AND ANALOGS THEREOF, AND NEW ANTIVIRAL AGENTS
  申请人：Hudlicky Tomas

  公开号：US20120252890A1

  公开（公告）日：2012-10-04

  The present application relates to processes for the preparation of intermediates useful in the manufacture of oseltamivir and the H 3 PO 4 salt of oseltamivir, Tamiflu®. The application further relates to novel intermediate and compounds and oseltamivir analogs and to pharmaceutical compositions comprising said analog compounds. The application further relates to a method of using the novel analogs of oseltamivir to treat or prevent influenza.

  本申请涉及用于制造奥司他韦和奥司他韦的H3PO4盐的中间体的制备过程。该申请还涉及新型中间体和化合物以及奥司他韦类似物和包含该类似物化合物的制药组合物。该申请还涉及使用新型奥司他韦类似物治疗或预防流感的方法。
• Polynucleotides for production of farnesyl dibenzodiazepinones
  申请人：Farnet M. Chris

  公开号：US20060172395A1

  公开（公告）日：2006-08-03

  This invention provides genes and their encoded proteins, involved in the biosynthesis of farnesyl dibenzodiazepinones, including ECO-04601. The invention relates to expression vectors comprising the genes and to host cell transformed with these vectors. The invention further relates to methods of producing farnesyl dibenzodiazepinone compounds using the genes and proteins of the invention, for example, involving expression of biosynthetic pathway genes in transformed host cells.

  该发明提供了参与法尼酰二苯并二氮环酮（包括ECO-04601）生物合成的基因及其编码的蛋白质。该发明涉及包含这些基因的表达载体以及转化为这些载体的宿主细胞。该发明进一步涉及使用该发明中的基因和蛋白质生产法尼酰二苯并二氮环酮化合物的方法，例如在转化的宿主细胞中表达生物合成途径基因。
• Farnesyl dibenzodiazepinone, processes for its production and its use as a pharmaceutical
  申请人：Bachmann O. Brian

  公开号：US20050043297A1

  公开（公告）日：2005-02-24

  This invention relates to a novel farnesylated dibenzodiazepinone, named ECO-04601, its pharmaceutically acceptable salts and derivatives, and to methods for obtaining such compounds. One method of obtaining the ECO-04601 compound is by cultivation of a novel strain of Micromonospora sp., 046-ECO11; another method involves expression of biosynthetic pathway genes in transformed host cells. The present invention further relates to Micromonospora sp. strain 046-ECO11, to the use of ECO-04601 and its pharmaceutically acceptable salts and derivatives as pharmaceuticals, in particular to their use as inhibitors of cancer cell growth, bacterial cell growth, mammalian lipoxygenase, and to pharmaceutical compositions comprising ECO-04601 or a pharmaceutically acceptable salt or derivative thereof. Finally, the invention relates to novel polynucleotide sequences and their encoded proteins, which are involved in the biosynthesis of ECO-04601.

  本发明涉及一种新型的法尼酰化二苯并二氮杂环酮，命名为ECO-04601，其药学上可接受的盐和衍生物，以及获得这种化合物的方法。获得ECO-04601化合物的一种方法是通过培养一种新的微单孢菌株，046-ECO11；另一种方法涉及在转化的宿主细胞中表达生物合成途径基因。本发明还涉及微单孢菌株046-ECO11的使用，以及ECO-04601及其药学上可接受的盐和衍生物作为药物的使用，特别是作为癌细胞生长抑制剂、细菌细胞生长抑制剂、哺乳动物脂肪氧合酶抑制剂，以及包含ECO-04601或其药学上可接受的盐或衍生物的药物组合物。最后，本发明涉及新的多核苷酸序列及其编码的蛋白质，这些蛋白质参与ECO-04601的生物合成。
• Farnesyl dibenzodiazepinone and processes for its production
  申请人：McAlpine James B.

  公开号：US20080199940A1

  公开（公告）日：2008-08-21

  This invention relates to a novel farnesylated dibenzodiazepinone, named ECO-04601, its pharmaceutically acceptable salts and derivatives, and to methods for obtaining such compounds. One method of obtaining the ECO-04601 compound is by cultivation of a novel strain of Micromonospora sp., 046-ECO11; another method involves expression of biosynthetic pathway genes in transformed host cells. The present invention further relates to Micromonospora sp. strain 046-ECO11, to the use of ECO-04601 and its pharmaceutically acceptable salts and derivatives as pharmaceuticals, in particular to their use as inhibitors of cancer cell growth, bacterial cell growth, mammalian lipoxygenase, and to pharmaceutical compositions comprising ECO-04601 or a pharmaceutically acceptable salt or derivative thereof. Finally, the invention relates to novel polynucleotide sequences and their encoded proteins, which are involved in the biosynthesis of ECO-04601.

  本发明涉及一种新型的法尼醇基二苯并二氮杂环酮，命名为ECO-04601，其药物可接受的盐和衍生物，以及获得这种化合物的方法。获得ECO-04601化合物的一种方法是通过培养一种新的微单孢菌株Micromonosporasp. 046-ECO11; 另一种方法涉及在转化的宿主细胞中表达生物合成途径基因。本发明还涉及Micromonosporasp.株046-ECO11的使用，以及ECO-04601及其药物可接受的盐和衍生物作为药物的使用，特别是作为癌细胞生长抑制剂，细菌细胞生长抑制剂，哺乳动物脂氧合酶以及包含ECO-04601或其药物可接受的盐或衍生物的药物组合物。最后，本发明涉及新的多核苷酸序列及其编码的蛋白质，这些蛋白质参与ECO-04601的生物合成。
• FARNESYL DIBENZODIAZEPINONE AND PROCESSES FOR ITS PRODUCTION
  申请人：ZAZOPOULOS Emmanuel

  公开号：US20090263886A1

  公开（公告）日：2009-10-22

  This invention relates to a novel farnesylated dibenzodiazepinone, named ECO-04601, its pharmaceutically acceptable salts and derivatives, and to methods for obtaining such compounds. One method of obtaining the ECO-04601 compound is by cultivation of a novel strain of Micromonospora sp., 046-ECO11; another method involves expression of biosynthetic pathway genes in transformed host cells. The present invention further relates to Micromonospora sp. strain 046-ECO11, to the use of and its pharmaceutically acceptable salts and derivatives as pharmaceuticals, in particular to their use as inhibitors of cancer cell growth, bacterial cell growth, mammalian lipoxygenase, and to pharmaceutical compositions comprising ECO-04601 or a pharmaceutically acceptable salt or derivative thereof. Finally, the invention relates to novel polynucleotide sequences and their encoded proteins, which are involved in the biosynthesis of ECO-04601.

  本发明涉及一种新型的法尼酰化二苯并二氮平酮，名为ECO-04601，其药学上可接受的盐和衍生物，以及获得这种化合物的方法。获得ECO-04601化合物的一种方法是通过培养一种新的微单孢菌株Micromonosporasp.，046-ECO11；另一种方法涉及在转化的宿主细胞中表达生物合成途径基因。本发明还涉及Micromonosporasp.株系046-ECO11的使用及其药学上可接受的盐和衍生物作为药物，特别是它们作为抑制癌细胞生长、细菌细胞生长、哺乳动物脂氧合酶的药物的使用，以及包含ECO-04601或其药学上可接受的盐或衍生物的药物组合物。最后，本发明涉及新的多核苷酸序列及其编码的蛋白质，这些蛋白质参与ECO-04601的生物合成。